STOCK TITAN

Exagen Inc. - XGN STOCK NEWS

Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.

Exagen Inc. (NASDAQ: XGN) is a leading provider of advanced diagnostic solutions focused on autoimmune rheumatic diseases. With its headquarters in Carlsbad, California, Exagen operates a CLIA-certified and CAP-accredited laboratory dedicated to improving patient outcomes through innovative testing solutions.

Exagen's core business revolves around its Avise® brand, which encompasses a suite of ten proprietary diagnostic tests designed to provide accurate, timely, and differential diagnoses for autoimmune conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis. These tests empower physicians and patients with objective data to better manage and treat these complex diseases.

In recent developments, Exagen has entered an exclusive license agreement with Johns Hopkins University to develop novel lupus nephritis biomarkers. This collaboration aims to create non-invasive assays that offer unique clinical insights into lupus nephritis, enhancing diagnostic and treatment options.

Financially, Exagen reported revenue of $13.4 million for Q3 2023. Despite a net loss of $5.4 million for the same period, the company has shown improvements in key performance metrics such as adjusted EBITDA, which stood at $(3.6) million compared to $(6.1) million in Q3 2022. With cash and cash equivalents of $28.4 million as of September 30, 2023, Exagen is well-positioned to continue its growth and innovation.

Committed to personalized medicine, Exagen collaborates closely with community rheumatologists to ensure their diagnostic solutions meet the evolving needs of the medical community. Their focus on patient-centric care and continuous product enhancement underscores their mission to provide clarity in autoimmune disease decision-making.

For more detailed information, please visit the company's websites at exagen.com and avisetest.com.

Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) and Johns Hopkins University announced an exclusive license agreement to develop novel patented biomarkers for therapeutic management of lupus nephritis patients. The agreement grants Exagen worldwide exclusive rights to an invention from the laboratory of Michelle Petri, MD, MPH, and Andrea Fava, MD. The biomarkers aim to provide unique clinical insight into a patient’s lupus nephritis in a non-invasive manner, aiding diagnostic and treatment decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
-
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16th, 2023. Exagen's President and CEO, John Aballi, and CFO, Kamal Adawi, will present at 9:30 AM ET. The webcast of the presentation can be accessed on Exagen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. will release its financial results for Q3 2023 on November 13, 2023. The conference call to review the results will be hosted by the President and CEO, John Aballi, and the CFO, Kamal Adawi. Interested parties can access the call via dial-in or webcast. A replay of the call will be available until November 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
Rhea-AI Summary
Exagen Inc. accepted five abstracts at the ACR Convergence 2023, showcasing their autoimmune testing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Exagen Inc. to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. reports Q2 2023 financial results with record CTD test delivery and increased revenue. Gross margin improves to 58.7%. Net loss decreases. Cash and cash equivalents at $31.5 million. Q3 2023 revenue guidance of $10M-$10.5M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) to Participate in Canaccord Genuity 43rd Annual Growth Conference, Presenting Autoimmune Testing Solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc., a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, on August 7, 2023. A conference call will be hosted by the President and CEO, John Aballi, and CFO, Kamal Adawi, to review the results. Interested parties can access the call via dial-in or webcast. A replay of the call will be available until August 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Exagen Inc. announced the appointment of Paul Kim as a member of their Board of Directors. Mr. Kim is currently the CFO of Fulgent Genetics and has led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021. He brings over 30 years of accounting and finance experience to the role.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences

FAQ

What is the current stock price of Exagen (XGN)?

The current stock price of Exagen (XGN) is $4.7 as of December 3, 2024.

What is the market cap of Exagen (XGN)?

The market cap of Exagen (XGN) is approximately 69.3M.

What is Exagen Inc. known for?

Exagen Inc. is known for its advanced diagnostic solutions for autoimmune rheumatic diseases, primarily marketed under the Avise® brand.

Where is Exagen Inc. located?

Exagen Inc. is headquartered in Carlsbad, California.

What recent partnerships has Exagen Inc. entered into?

Exagen recently entered an exclusive license agreement with Johns Hopkins University to develop novel lupus nephritis biomarkers.

How did Exagen Inc. perform financially in Q3 2023?

Exagen reported revenue of $13.4 million and a net loss of $5.4 million for Q3 2023, with improvements in key performance metrics.

What is the Avise® brand?

Avise® is Exagen's proprietary brand of diagnostic tests designed to provide accurate and timely diagnoses for autoimmune rheumatic diseases.

How does Exagen Inc. contribute to personalized medicine?

Exagen's Avise® tests provide objective information to help physicians and patients make more informed decisions for better disease management.

What is Exagen's mission?

Exagen aims to provide clarity in autoimmune disease decision-making to improve patient outcomes.

What was Exagen's adjusted EBITDA for Q3 2023?

Exagen's adjusted EBITDA for Q3 2023 was $(3.6) million, showing improvement from $(6.1) million in Q3 2022.

What resources does Exagen offer for lupus awareness?

Exagen runs campaigns and provides resources on their websites and social media platforms to raise lupus awareness and support affected patients.

How can I contact Exagen Inc. for investor relations?

For investor relations, contact Ryan Douglas at rdouglas@exagen.com or call 760.560.1525.

Exagen Inc.

Nasdaq:XGN

XGN Rankings

XGN Stock Data

69.31M
9.12M
29.74%
57.22%
0.3%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
VISTA